Showing results (151-160 of 223) with videos related to

Sort By:
Pageof 23
Multiple Sclerosis and Related Disorders|October 12, 2020
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosisTimothy L Vollmer, Jeffrey A Cohen, Enrique Alvarez, et al.
Archives of Physical Medicine and Rehabilitation|May 9, 2003
Static magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-controlled trialMichael I Weintraub, Gil I Wolfe, Richard A Barohn, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2022
Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosisJeffrey A Cohen, Fred D Lublin, Christoper Lock, et al.
The Lancet. Neurology|May 17, 2011
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS studyBhupendra Khatri, Frederik Barkhof, Giancarlo Comi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 18, 2026
GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trialAaron Miller, Jeffrey A Cohen, Arnon Karni, et al.
Multiple Sclerosis and Related Disorders|January 17, 2021
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MSJohn DeLuca, Sven Schippling, Xavier Montalban, et al.
Muscle & Nerve|April 13, 2011
Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & RehabilitationVera Bril, John D England, Gary M Franklin, et al.
Neurology. Clinical Practice|August 25, 2018
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centersBrandi Vollmer, Daniel Ontaneda, Anasua Bandyopadhyay, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 8, 2022
Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT studyYang Mao-Draayer, Jeffrey A Cohen, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 23, 2016
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosisDiego Cadavid, Jeffrey A Cohen, Mark S Freedman, et al.
Pageof 23